A multicenter study of relapsed pediatric acute promyelocytic leukemia protocol

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082058

Enrollment

Unknown

Registered

2024-03-20

Start date

2024-03-20

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute promyelocytic leukemia in children and adolescents

Interventions

Venetoclax group:Venetoclax-based treatment protocol

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: ? Children with APL eligible for hematological or molecular biological relapse. ? Age = 18 years. ? Obtain informed consent signed by the patient or guardian.

Exclusion criteria

Exclusion criteria: ? Children who are allergic to Venetoclax. ? Children and guardians who are unable to understand or comply with the study protocol.

Design outcomes

Primary

Measure	Time frame
OS;EFS;	—

Secondary

Measure	Time frame
Time to achieve hematologic complete remission;Time to achieve molecular complete remission;Early mortality;Cumulative disease relapse rate;	—

Countries

China

Contacts

Public ContactHuyong Zheng

Beijing Children's Hospital, Capital Medical University

zhenghuyong@bch.com.cn+86 133 7011 5036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026